Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management
Authors
Keywords
-
Journal
Current Opinion in Endocrinology Diabetes and Obesity
Volume 28, Issue 4, Pages 427-434
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-06-29
DOI
10.1097/med.0000000000000652
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Endocrine toxicities of immune checkpoint inhibitors
- (2021) Jordan J. Wright et al. Nature Reviews Endocrinology
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Hypophysitis (including IgG4 and immunotherapy)
- (2020) Anna Angelousi et al. NEUROENDOCRINOLOGY
- Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
- (2020) Seiichi Yano et al. EUROPEAN JOURNAL OF CANCER
- MECHANISMS IN ENDOCRINOLOGY: Autoimmune hypopituitarism: novel mechanistic insights
- (2020) Yutaka Takahashi EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH
- (2020) M. S. Siddiqui et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
- (2020) Tomoko Kobayashi et al. Journal for ImmunoTherapy of Cancer
- Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
- (2020) Zoe Quandt et al. Annual Review of Medicine
- Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma: a new emerging treatment?
- (2020) Bastiaan Sol et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
- (2020) Marina Tsoli et al. Cancer Management and Research
- Ipilimumab-induced hypophysitis, a single academic center experience
- (2019) Travis Snyders et al. Pituitary
- Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
- (2019) Alexander Faje et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
- (2019) Frédérique Albarel et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
- (2019) Eva Kassi et al. Cancer Medicine
- Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
- (2019) Sahityasri Thapi et al. Journal for ImmunoTherapy of Cancer
- Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management
- (2019) Jaydira Del Rivero et al. ONCOLOGIST
- Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors
- (2019) Ruth Percik et al. AUTOIMMUNITY REVIEWS
- PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
- (2019) Anupam Kotwal et al. THYROID
- Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
- (2019) Julie Garon-Czmil et al. Scientific Reports
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
- (2018) Romualdo Barroso-Sousa et al. CANCER
- Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
- (2018) Sunita M. C. De Sousa et al. Pituitary
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- ImmuneCheckpoint Inhibitor-Induced Hypoparathyroidism Associated with Calcium-Sensing Receptor-Activating Autoantibodies
- (2018) Paramarajan Piranavan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- French Endocrine Society Guidance on endocrine side effects of immunotherapy
- (2018) F Castinetti et al. ENDOCRINE-RELATED CANCER
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
- (2017) Emma S Scott et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
- (2017) Chen Zhao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
- (2016) Patrizio Caturegli et al. AMERICAN JOURNAL OF PATHOLOGY
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
- (2013) Francesco Torino et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ipilimumab-induced autoimmune adrenalitis
- (2013) Le Min et al. Lancet Diabetes & Endocrinology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now